Beximco Pharma’s muscle relaxant drug Methocarbamol has been cleared for the United States.
The Bangladesh drugmaker said in a statement on Monday that it received approval from the US Food and Drug Administration or FDA.
This is the fourth product approval for Beximco in the US market and it expects to launch the product during last quarter of 2017, according to the statement.
The company said there were four active generic players for Methocarbamol in the USA — Camber, Qualitest, West-Ward and Solco.
“I firmly believe this approval and our growing pipeline for US will largely help us build our presence in the world’s largest pharma market in the coming years,” said Beximco Pharma’s Managing Director Nazmul Hassan.
In 2015, Beximco Pharma became the first Bangladeshi drugmaker to be audited and approved by the FDA.
It currently has a global footprint in more than 50 countries. (Source: bdnews24.com)